Changing the World through Tech

Nominet Trust proudly announced that Reverse the Odds has been named among the 2014 Nominet Trust 100 (NT100) - a global list of 100 inspiring ventures from around the world.

Dr Anne Kiltie hopes to understand when patients diagnosed with muscle invasive bladder cancer are more likely to respond to radiotherapy or should be offered surgery.

Projects featured on the list are using technology to tackle some of the world’s biggest social problems from education and human rights abuses to climate change and health.

Professor Gillies McKenna Receives Gold Medal

Professor Gillies McKenna, Head of the Department of Oncology, has been awarded the Gold Medal by the Royal College of Radiologists in recognition of the outstanding contribution that he has made to the field of radiation oncology.

At the award ceremony, held in London in November 2014, Professor McKenna also delivered the twelfth David Skeggs lecture, entitled Imaging and Targets: The Molecular Frontiers in Radiation Oncology.

Oxford Medical Sciences excels in REF 2014 exercise

Today’s Research Excellence Framework (REF 2014) results confirm the University of Oxford’s world leading position in medical sciences research.

Furthermore, the University overall has the largest volume of world leading research and impact submitted to the REF exercise.

The Department of Oncology is part of the Medical Sciences Division and submitted under Clinical Medicine, a unit of assessment in which we ranked top for overall quality.

Giulia Orlando

Giulia first visited Oxford immediately after her Undergraduate degree to undertake a summer internship with Professor Ian Tomlinson; she then joined the CRUK/MRC Oxford Institute for Radiation Oncology in 2010 having completed her Turin University Bachelors and Master’s degrees in Bio-molecular Biotechnology. Giulia was awarded a fees-only MRC award and the prestigious Scatcherd European scholarship to work on DNA repair regulation in cancer with Professor Grigory Dianov. Her PhD work suggests a link between PARP1 activation and up-regulation of the tumour suppressor protein ARF.

Angelos Papaspyropoulos

Angelos came to the UK to undertake his graduate studies after completing his undergraduate degree in Biology at Aristotle University of Thessaloniki. Funded by an MRC fees only award and a CRUK/MRC Oxford Institute for Radiation Oncology studentship, he started his DPhil with Associate Professor Eric O’Neil in 2010 on tumour suppressor signalling, the tumour microenvironment, and stem cell fate determination.

Tracy Underwood

Tracy graduated with a Bachelors in Physics from the University of Oxford and an MSc in Medical Engineering and Physics from King's College London. She then joined the CRUK/MRC Oxford Institute for Radiation Oncology to pursue an MRC-funded DPhil project on the dosimetry of small photon beams, supervised by Dr Mark Hill, Dr Helen Winter and Dr John Fenwick. To date, the key paper from Tracy's DPhil research, published in Physics in Medicine and Biology, has been downloaded over 11,000 times.

Monica Olcina del Molino

Originally from Spain, Monica joined the CRUK/MRC Oxford Institute for Radiation Oncology in 2009 from the University of Manchester with a 4-year first class degree in Pharmacy. She was in the first cohort of the Department of Oncology MSc in Radiation Biology as part of an MRC-funded 4-year programme in Radiobiology. Monica obtained a distinction in her MSc in 2010 and then started her DPhil project in the laboratory of Associate Professor Ester Hammond.

Peter O'Neill

My interests over the years have focussed on the chemistry and biochemical pathways involved in the repair of radiation-induced DNA damage and more recently have focussed on clustered DNA damage.


EudraCT number: 2011-000661-12 
Sponsor: University of Oxford

A randomised double blind phase 2 trial of whole brain radiotherapy with or without vandetanib in metastatic melanoma with brain metastases.

The aim is to compare whole brain radiotherapy (WBRT) with or without vandetanib in the treatment of patients with brain metastases from melanoma, in terms of progression free survival, overall survival and safety and tolerability of vandetanib in combination with radiotherapy.


About Us
We aim to enhance clinical and basic cancer research in Oxford with the ultimate goal of increasing cancer cure rates.
In Oxford, we have a great wealth of broad-ranging expertise and a powerful network of cancer researchers.
Study With Us
Our graduate training programmes for both scientists and clinicians are internationally recognised.
Subscribe to Department of Oncology RSS